Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess
PLOS One · 12.08.2026 · 21 (8) · e0355852
DOI: 10.1371/journal.pone.0355852 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.08.2026. Verfasst von Yiheng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Longgang Central Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Phthalazines, Histamine Antagonists, Piperidines, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Medical Science and Technology of Henan Province, Scientific Research Project of Colleges and Universities in Henan Province.
Abstract (Originalsprache)
Introduction
Antihistamines like azelastine and levocabastine are key in treating allergies, including allergic rhinitis, conjunctivitis, and urticaria. This study analyzed adverse drug reactions linked to these drugs using data from the WHO VigiAccess database, comparing their adverse drug reaction profiles to help physicians choose lower-risk options for personalized treatment.
Methods
A retrospective descriptive analysis was used, with data from WHO-VigiAccess on azelastine and levocabastine. Included were global patient demographics (age, gender, location) and details on illness systems/symptoms from direct and annual adverse drug reaction reports. Adverse drug reaction percentages for each drug were calculated for comparison.
Results
Over the study period, 11,592 adverse events related to both drugs were reported. Both had high rates of General disorders and administration site conditions. Azelastine showed more Nervous system disorders. Levocabastine had higher rates of endocrine disorders, injury/poisoning/procedural complications, and Nervous system disorders. The top five adverse events were: General disorders (4463, 36.7%), Nervous system (3475, 28.6%), Gastrointestinal (1558, 12.8%), Respiratory (1515, 12.5%), and Injury/poisoning (871, 7.2%). For SOC-reported ADRs, > 10% incidence occurred in 2 azelastine cases and 4 levocabastine cases.
Conclusion
Clinicians should note antihistamine ADRs. This study identifies common and specific reactions reported to the WHO, aiming to guide safer, more judicious use of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Longgang Central Hospital, Shenzhen, China.
- School of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Yiheng Li
Förderung
- National Natural Science Foundation of China
- Key Project of Medical Science and Technology of Henan Province
- Scientific Research Project of Colleges and Universities in Henan Province
Zitieren
APA
Li, Y., Zhu, J., Guo, Q., Liao, J., Li, L., Hu, J., & Zhang, X. (2026). Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess. PLOS One, 21(8), e0355852. https://doi.org/10.1371/journal.pone.0355852
Vancouver
Li Y, Zhu J, Guo Q, Liao J, Li L, Hu J, et al. Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess. PLOS One. 2026;21(8):e0355852. doi:10.1371/journal.pone.0355852
BibTeX
@article{Li2026,
author = {Li, Yiheng and Zhu, Jing and Guo, Qian and Liao, Jiaman and Li, Lixia and Hu, Jing and Zhang, Xiaoliang},
title = {Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0355852},
doi = {10.1371/journal.pone.0355852}
}
EUVIMED